Organogenesis Holdings Inc. (ORGO) Competitors & Peers
The 5 largest companies in the same industry as Organogenesis Holdings Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| JHPCY | Peer | $11.50 | P/E 32.9RSI 19Cap 76.3 B |
| GDERF | Peer | $191.38 | P/E 52.3RSI 44Cap 44.6 B |
| TAK | Peer | $18.86 | RSI 60Cap 60.2 B |
| GALDY | Peer | $39.45 | P/E 54.6RSI 49Cap 46.5 B |
| TKPHF | Peer | $37.00 | RSI 55Cap 59.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- CAHCustomer
Cardinal Health is a major distributor for Organogenesis, representing approximately 13% of gross revenues in FY2025.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKCustomer
McKesson acts as a key distributor for Organogenesis, representing approximately 42% of gross revenues in FY2025.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CORCustomer
Cencora (formerly AmerisourceBergen) is a major distributor for Organogenesis, representing approximately 19% of gross revenues in FY2025.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- CMSCustomer
CMS sets reimbursement rates that dictate the commercial viability of Organogenesis's skin substitutes for diabetic ulcers.
Model-inferred, unverified — treat as a lead, not evidence - VACustomer
The VA is a major purchaser of Organogenesis wound care products for veteran healthcare.
Model-inferred, unverified — treat as a lead, not evidence - MDXGCompetitor
MiMedx competes directly with Organogenesis in the skin substitute and amniotic allograft market (e.g., EpiFix competing with NuShield/Affinity).
Model-inferred, unverified — treat as a lead, not evidence - KERECISCompetitor
Kerecis (fish-skin biologics) is a rapidly growing competitor taking market share in the wound care sector.
Model-inferred, unverified — treat as a lead, not evidence - RCELCompetitor
Avita Medical (RECELL) competes in the burn and advanced wound healing market.
Model-inferred, unverified — treat as a lead, not evidence - SNNCompetitor
Smith & Nephew competes with Organogenesis in the advanced wound management and bioengineered skin substitute markets.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson acts as a major medical-surgical distributor helping fulfill ORGO's product distribution.
Model-inferred, unverified — treat as a lead, not evidence - VIZIENTPartner
Vizient awarded Organogenesis an Innovative Technology contract for PuraPly Antimicrobial and other wound care products, making them available to Vizient's hospital network.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal Health serves as a key wholesale distributor for routing Organogenesis products to clinical sites.
Model-inferred, unverified — treat as a lead, not evidence - LIFELINKSupplier
LifeLink Tissue Bank supplies human tissue allografts and donor tissues to Organogenesis for the production of amniotic/placental wound care products.
Model-inferred, unverified — treat as a lead, not evidence - VCELCompetitor
Organogenesis and Vericel compete in the cellular therapy and advanced wound care markets.
Model-inferred, unverified — treat as a lead, not evidence - IARTCompetitor
Integra LifeSciences competes with Organogenesis in the dermal templates and advanced wound matrix markets.
Model-inferred, unverified — treat as a lead, not evidence